N-acetylcysteine therapy reduces major adverse cardiovascular events in patients with type 2 diabetes mellitus. Sun M, Lu Z, Chen WM, Lv S, et al. Atherosclerosis 2025;402:119117.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sun M, Lu Z, Chen WM, Lv S, et al. N-acetylcysteine therapy reduces major adverse cardiovascular events in patients with type 2 diabetes mellitus. Atherosclerosis 2025;402:119117.
PMID: 39903949